Subscribe to stay informed!
Ocugen, a gene therapy and biopharmaceutical company in Malvern, has finalized its reverse merger with Histogenics, a publicly traded company in Boston, and is now…
Malvern-based Ocugen, a gene therapy and biopharmaceutical company that develops new treatments for rare and underserved eye diseases, has entered into a merger agreement…
Before we send you to this site, please subscribe to our daily newsletter.